Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation

Jacksonville, FL and Irvine, CA – March 11, 2019 – Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin in patients …

Espero BioPharma to Present at BIO CEO & Investor conference on February 11, 2019

Jacksonville, FL and Irvine, CA – February 6, 2019 – Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Dr. Lee Golden, Chief Medical Officer, will present at the BIO CEO & Investor Conference on Monday, February 11th, 2019 at 10:30 AM ET. The …

Espero BioPharma Provides Update on the Development of Tecarfarin
for the Treatment of Mechanical Heart Valve Patients in China

Jacksonville, FL and Irvine, CA – Jan. 24, 2019 — Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis and cardiac rhythm control, today announced that Lee’s Pharmaceutical Holdings Limited and its subsidiaries (collectively “Lee’s Pharmaceutical”) has completed its Phase I study of tecarfarin in healthy volunteers in Hong Kong. Lee’s …

Espero BioPharma Appoints Lee Golden, M.D., as Chief Medical Officer

Jacksonville, FL and Irvine, CA – October 9, 2018 – Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs to treat forms of cardiovascular disease, today announced the appointment of Lee Golden, M.D. as Chief Medical Officer.  In his role as a member of the executive leadership team, Dr. Golden will direct …

Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018

Jacksonville, FL – May 30, 2018 — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET on Wednesday, June 6, 2018. The conference will be held at …

Espero BioPharma to Present at BIO CEO & Investor Conference on February 13, 2018

Jacksonville, FL and Irvine, CA – February 7, 2018 – Espero BioPharma, a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the BIO CEO & Investor Conference on Tuesday, February 13th, 2018 at 10:00 AM ET. The conference will be held …

Area company Espero looks to hold trials for new drugs

Jacksonville, FL – January 3, 2018 (The Florida Times Union) – In 2014 Quang Pham founded Espero Pharmaceuticals, which the Jacksonville Business Journal called “the fastest-growing company in Jacksonville” last year. Now the company, renamed Espero BioPharma after a merger, is preparing to launch new clinical trials for two drugs Pham, its chairman and CEO, believes can become “standards of …

Espero BioPharma to Present at Biotech Showcase on January 9, 2018

Jacksonville, FL and Irvine, CA – January 3, 2018 — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the Biotech Showcase 2018 on January 9th, 2018 at 11:45 AM PT / 2:45 PM ET. The conference will be held …

Espero BioPharma Provides Corporate Update and 2018 Objectives

JACKSONVILLE, Fla. and IRVINE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced a strategic update on its clinical and regulatory strategies for tecarfarin, an oral anticoagulant (OAC). Tecarfarin and budiodarone were added to Espero’s product pipeline through the company’s merger with …

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected to occur in the second …